Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice

Journal of Clinical Investigation

Volumn 112, Issue 1, 2003, Pages 83-90

  Masuzaki, Hiroaki ^a   Yamamoto, Hiroshi ^a   Kenyon, Christopher J ^b   Elmquist, Joel K ^a   Morton, Nicholas M ^b   Paterson, Janice M ^b   Shinyama, Hiroshi ^a   Sharp, Matthew G F ^b   Fleming, Stewart ^c   Mullins, John J ^b   Seckl, Jonathan R ^b   Flier, Jeffrey S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; COMPLEMENTARY RNA; GA 0113; GLUCOCORTICOID; MESSENGER RNA; UNCLASSIFIED DRUG; HYDROXYSTEROID DEHYDROGENASE; SODIUM CHLORIDE;

ADIPOSE TISSUE; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; DYSLIPIDEMIA; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERTENSION; INSULIN RESISTANCE; KIDNEY PROXIMAL TUBULE; METABOLIC SYNDROME X; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SALT INTAKE; ANIMAL; ENZYMOLOGY; KIDNEY; MALE; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

11-BETA-HYDROXYSTEROID DEHYDROGENASES; ADIPOSE TISSUE; ANIMALS; GLUCOCORTICOIDS; HYDROXYSTEROID DEHYDROGENASES; HYPERTENSION; KIDNEY; MALE; MICE; MICE, TRANSGENIC; RENIN-ANGIOTENSIN SYSTEM; SODIUM CHLORIDE;

EID: 85047693986     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI17845     Document Type: Article

References (70)

1. Spiegelman, B.M., and Flier, J.S. 2001. Obesity and the regulation of energy balance. Cell. 104:531-543.
2. Matsuzawa, Y., Funahashi, T., and Nakamura, T. 1999. Molecular mechanism of metabolic syndrome X: contributions of adipocytokines, adipocyte-derived bioactive substances. Ann. N. Y. Acad. Sci. 892:146-154.
3. Kahn, B.B., and Flier, J.S. 2000. Obesity and insulin resistance. J. Clin. Invest. 106:473-481.
4. Aizawa-Abe, M., et al. 2000. Pathophysiological role of leptin in obesity-related hypertension. J. Clin. Invest. 105:1243-1252.
5. Busetto, L. 2001. Visceral obesity and the metabolic syndrome. Effect of weight loss. Nutr. Metab. Cardiovasc. Dis. 11:195-204.
6. Kopelman, P.G. 2000. Obesity as a medical problem. Nature. 404:635-643.
7. Diep, Q.N., et al. 2002. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-induced rats. Role of peroxisome proliferator-activated receptor-γ. Circulation. 105:2296-2302.
8. Hodge, G., Ye, V.Z., and Duggan, K.A. 2002. Salt-sensitive hypertension resulting from nitric oxide synthase inhibition is associated with loss of regulation of angiotensin II in the rat. Exp. Physiol. 87:1-8.
9. Wajchenberg, B.L. 2000. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr. Rev. 21:697-738.
10. Inagami, T., et al. 1999. Angiotensin receptors: molecular biology and signalling. Clin. Exp. Pharmacol. Physiol. 26:544-549.
11. Walker, W.G., Whelton, P.K., Saito, H., Russel, R.P., and Hermann, J. 1979. Relation between blood pressure and renin, renin substrate, angiotensin II, aldosterone and urinary sodium and potasium in 574 ambulatory subjects. Hypertension. 1:287-291.
12. Lalouel, J.M., Rohrwasser, A., Terreros, D., Morgan, T., and Ward, K. 2001. Angiotensinogen in essential hypertension: from genetics to nephrology. J. Am. Soc. Nephrol. 12:606-615.
13. Ailhaud, G., Teboul, M., and Massiera, F. 2002. Angiotensinogen, adipocyte differentiation and fat mass enlargement. Curr. Opin. Clin. Nutr. Metab. 5:385-389.
14. Rotimi, C., et al. 1997. Hypertension, serum angiotensinogen, and molecular variants of the angiotensinogen gene among Nigerians. Circulation. 95:2348-2350.
15. Pratt, J.H., et al. 1998. Serum angiotensinogen concentration in relation to gonadal hormones, body size, and genotype in growing young people. Hypertension. 32:875-879.
16. Massiera, F., et al. 2001. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J. 15:2727-2739.
17. Montague, C.T., and O'Rahilly, S. 2000 The perils of portliness. Cause and consequences of visceral adipocity. Diabetes. 49:883-888.
18. Peeke, P.M., and Chrousos, G.P. 1995. Hypercortisolism and obesity. Ann. N. Y. Acad Sci. 771:665-676.
19. Seckl, J.R., and Walker, B.R. 2001. Minireview: 11β-hydroxysteroid dehydrogenase type 1 - a tissue·specific amplifier of glucocorticoid action. Endocrinology. 142:1371-1376.
20. Sandeep, T.C., and Walker, B.R. 2001. Pathophysiology of modulation of local glucocorticoid levels by 11beta-hydroxysteroid dehydrogenases. Trends Endocrinol. Metab. 12:446-453.
21. Tomlinson, J.W., et al. 2002. Absence of Cushingoid phenotype in a patient with Cushing's disease due to defective cortisone to cortisol conversion. J. Clin. Endocrinol. Metab. 87:57-62.
22. Bjorntorp, P., and Rosmond, R. 2000. Obesity and cortisol. Nutrition. 16:924-936.
23. Chrousos, G.P., and Gold, P.W. 1992. The concept of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA. 267:1244-1252.
24. Reynolds, R.M., et al. 2002. Skeletal muscle glucocorticoid receptor density and insulin resistance. JAMA. 287:2505-2506.
25. Rask, E., et al. 2001. Tissue-specific dysregulation of cortisol metabolism in human obesity. J. Clin. Endocrinol. Metab. 86:1418-1421.
26. Rask, E., et al. 2002. Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11β-hydroxysteroid dehydrogenase type 1 activity. J. Clin. Endocrinol. Metab. 87:3330-3336.
27. Whorwood, C.B., Donovan, S.J., Flanagan, D., Phillips, D.I.W., and Byrne, C.D. 2002. Increased glucocorticoid receptor expression in human skeletal muscle cells may contribute to the pathogenesis of the metabolic syndrome. Diabetes. 51:1066-1075.
28. Paulmyer-Lacroix, O., Bouliu, S., Oliver, C., Alessi, M.-C., and Grino, M. 2002. Expression of the mRNA coding for 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an in situ hybridization study. J. Clin. Endocrinol. Metab. 87:2701-2705.
29. Livingstone, D.E., et al. 2000. Understanding the role of glucocorticoids in obesity: tissue-specific alterations of corticosterone metabolism in obese Zucker rats. Endocrinology. 141:560-563.
30. Livingstone, D.E., Kenyon, C.J., and Walker, B.R. 2000. Mechanisms of dysregulation of 11beta-hydroxysteroid dehydrogenase type 1 in obese Zucker rats. J. Endocrinol. 167:533-539.
31. Kotelevstev, Y., et al. 1997. 11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc. Natl. Acad. Sci. U. S. A. 94:14924-14929.
32. Morton, N.M., et al. 2001. Improved lipid and lipoprotein profile, hapatic insulin sensitivity, and glucose tolerance in 11β-hydroxysteroid dehydrogenase type 1 null mice. J. Biol. Chem. 276:41293-41300.
33. Morton, N.M., et al. 2002. 11β-hydroxysteroid dehydrogenase type 1 null mice resist dietary obesity and its metabolic consequences. Program of the 84th annual meeting of the Endocrine Society. San Francisco, California, USA. 87 (Abstr.)
34. Masuzaki, H., et al. 2001. A transgenic model of visceral obesity and the metabolic syndrome. Science. 294:2166-2170.
35. Yamamoto, H., et al. 2002. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J. Clin. Invest. 110:43-52.
36. Williams, T.D., Chambers, J.B., Henderson, R.P., Rashotte, M.E., and Overton, J.M. 2002. Cardiovascular responses to caloric restriction and thermoneutrality in C57BL/6J mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 282:R1459-R1467.
37. 1-receptor antagonist. J. Cardiovasc. Pharmacol. 34:526-532.
38. Morton, J.J., and Wallace, E.C.H. 1983. The importance of the renin-angiotensin system in the development and maintenance of hypertension in the two-kidney one clip hypertensive rat. Clin. Sci. 64:359-370.
39. Kotelevtsev, Y., et al. 1999. Hypertension in mice lacking 11β-hydroxysteroid dehydrogenase type 2. J. Clin. Invest. 103:683-689.
40. Llorens-Cortes, C., Greenberg, B., Huang, H., and Corval, P. 1994. Tissue expression and regulation of type 1 angiotensin II receptor subtypes by quantitative reverse transcriptase chain reaction analysis. Hypertension. 24:538-548.
41. Basett, M.H., Zhang, Y., Clyne, C., White, P.C. and Rainey, W.E. 2002. Differential regulation of aldosterone synthetase and 11beta-hydroxylase transcription by steroidogenic factor-1. J. Mol. Endocrinol. 28:125-135.
42. Butz, G.M., and Davisson, R.L. 2001. Long-term telemetric measurement of cardiovascular parameters in awake mice: a physiological genomics tool. Physiol. Genomics. 5:89-97.
43. Shimada, K., et al. 2001. Early morning surge in blood pressure. Blood Press. Monit. 6:349-353.
44. Redon, J., Rosa-Cusachs, A., and Mora-Macia, J. 2002. Uncontrolled early morning blood pressure in medicated patients: the ACAMPA study. Blood Press. Monit. 7:111-116.
45. Engeli, S., and Sharma, A.M. 2002. Emerging concepts in the pathophysiology and treatment of obesity-associated hypertension. Curr. Opin. Cardiol. 17:355-359.
46. Frederich, R.C., Jr., Kahn, B.B., Peach, M.J., and Flier, J.S. 1992. Tissue-specific nutritional regulation of angiotensinogen in adipose tissue. Hypertension. 19:339-344.
47. Aubert, J., Darimont, C., Safonova, I., Ailhoud, G., and Negrel, R. 1997. Regulation by glucocorticoids of angiotensinogen gene expression and secretion in adipose cells. Biochem. J 328:701-706.
48. van Harmelen, V., et al. 2000. Increased adipose angiotensinogen gene expression in human obesity. Obes. Res. 8:337-341.
49. van Harmelen, V., et al. 2000. The association of human adipose angiotensinogen gene expression with abdominal fat distribution in obesity. Int. J. Obes. Relat. Metab. Disord. 24:673-678.
50. Miller, J.Z., Weinberger, M.H., Christian, J.C., and Daugherty, S.A. 1987. Familial resemblance in the blood pressure response to sodium retention. Am. J. Epidemiol. 126:822-830.
51. Poch, E., et al. 2001. Molecular basis of salt sensitivity in human hypertension. Evaluation of renin-angiotensin-aldosterone system gene polymorphisms. Hypertension. 38:1204-1209.
52. Cowley, A.W., Jr. 1997. Genetic and nongenetic determinants of salt sensitivity and blood pressure. Am. J. Clin. Nutr. 65(Suppl.):S587-S593.
53. Weinburger, M.H., Miller, J.Z., Luft, F.C., Grim, C.E., and Finberg, N.S. 1986. Definitions and characteristics of sodium sensitivity and blood pressure resistance. Hypertension. 8(Suppl. II):II127-II134.
54. De la Sieera, A., et al. 1996. Fluid, ionic and hormonal changes induced by high salt intake in salt-sensitive and salt-resistant hypertensive patients. Clin. Sci. 91:155-161.
55. Sugiyama, F., et al. 2001. Concordance of murine quantitative trait loci for salt-induced hypertension with rat and human loci. Genomics. 71:70-77.
56. O'Brien, E., Sheridan, J., and O'Malley, K. 1988. Dippers and non-dippers. Lancet. 13:397.
57. Engeli, S., and Sharma, A.M. 2001. The renin-angiotensin system and natriuretic peptides in obesity-associated hypertension. J. Mol. Med. 79:21-29.
58. Masuzaki, H., et al. 1996. Regulation of very-low-density lipoprotein receptor in hypertrophic rat heart. Circ. Res. 78:8-14.
59. Johnson, R.J., et al. 1992. Renal injury from angiotensin II-mediated hypertension. Hypertension. 19:464-474.
60. Pradevand, S., et al. 1999. A mouse model for Liddle's syndrome. J. Am. Soc. Nephrol. 10:2527-2533.
61. Hadoke, P.W., et al. 2001. Endothelial cell dysfunction in mice after transgenic knockout of type 2, but not type 1, 11beta-hydroxysteroid dehydrogenase. Circulation 104:2832-2837.
62. Stepp, D.W., and Frisbee, J.C. 2002. Augmented adrenergic vasoconstriction in hypertensive diabetic obese Zucker rats. Am. J. Physiol. Heart Circ. Physiol. 282:H816-H820.
63. Villiquette, R.A., Koletsky, R.J., and Ernsberger, P. 2002. Plasma glucagon and free fatty acid responses to a glucose load in the cbese spontaneous hypertensive rat (SHROB) model of metabolic syndrome X. Exp. Biol. Med. 227:164-170.
64. Mills, E., Kuhn, C.M., Feiglos, M.N., and Surwit, R. 1993. Hypertension in CB57BL/6J mouse model of non-insulin dependent diabetes mellitus. Am. J. Physiol. 264:R73-R78.
65. Contreras, R.J., and Williams, V.L. 1989. Dietary obesity and weight cycling: effects on blood pressure and heart rate in rats. Am. J. Physiol. 256:R1209-R1219.
66. Katovich, M.J., et al. 2001. Gene therapy attenuates the elevated blood pressure and glucose intolerance in an insulin-resistant model of hypertension. J. Hypertens. 19:1553-1558.
67. Montani, J. P., Antic, V., Yang, Z., and Dulloo, A. 2002. Pathways from obesity to hypertension: from the perspective of a vicious triangle. Int. J. Obes. Relat. Metab. Disord. 26(Suppl. 2):S28-S38.
68. Henriksen, E.J., Jacob, S., Kinnick, T.R., Teachey, M.K. and Krekler, M. 2001. Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension. 38:884-890.
69. Folli, F., et al. 1999. Crosstalk between insulin and angiotensin II signalling systems. Exp. Clin. Endocrinol. Diabetes. 107:133-139.
70. Ogihara, T., et al. 2002. Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension. 40:872-879.